Ferric Carboxymaltose - Sichuan Huiyu Pharmaceutical
Alternative Names: Ferric Carboxymaltose injectionLatest Information Update: 08 Dec 2025
At a glance
- Originator Sichuan Huiyu Pharmaceutical
- Class
- Mechanism of Action Iron modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 02 Apr 2025 Preclinical trials in Unspecified in China (IV) prior to April 2024 (NCT06895993)
- 26 Mar 2025 Sichuan Huiyu Pharmaceutical plans to initiate a phase I trial in healthy volunteers in China (IV) (NCT06895993)